Patents by Inventor Philip Marvin Weintraub

Philip Marvin Weintraub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted AZA-indoles as inhibitors of poly(ADP-ribose) polymerase (PARP)
    Patent number: 8008491
    Abstract: The present invention relates to a series of substituted aza-indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: August 30, 2011
    Assignee: Aventis Pharmaceuticals, Inc.
    Inventors: John Ziqi Jiang, Jack Roger Koehl, Shujaath Mehdi, Neil Moorcroft, Kwon Yon Musick, Philip Marvin Weintraub, Paul Robert Eastwood
  • Thienopyrazoles
    Patent number: 7928231
    Abstract: Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: April 19, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: John Gerard Jurcak, Matthieu Barrague, Timothy Alan Gillespy, Michael Louis Edwards, Kwon Yon Musick, Philip Marvin Weintraub, Yan Du, Ramalinga M. Dharanipragada, Ashfaq Ahmad Parkar
  • THIENOPYRAZOLES
    Publication number: 20100056514
    Abstract: Thienopyrazoles, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).
    Type: Application
    Filed: March 26, 2009
    Publication date: March 4, 2010
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: John Gerard JURCAK, Matthieu BARRAGUE, Timothy Alan GILLESPY, Michael Louis EDWARDS, Kwon Yon MUSICK, Philip Marvin WEINTRAUB, Yan DU, Ramalinga M. DHARANIPRAGADA, Ashfaq Ahmad PARKAR
  • SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
    Publication number: 20080255350
    Abstract: The present invention relates to a series of substituted aza-indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Application
    Filed: June 17, 2008
    Publication date: October 16, 2008
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: John Z. JIANG, Jack Roger KOEHL, Shujaath MEHDI, Neil MOORCROFT, Kwon Yon MUSICK, Philip Marvin WEINTRAUB, Paul Robert EASTWOOD
  • Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)
    Patent number: 7405300
    Abstract: The present invention relates to a series of substituted indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: July 29, 2008
    Assignee: Aventis Pharmaveuticals Inc.
    Inventors: John Z. Jiang, Jack Roger Koehl, Shujaath Mehdi, Neil David Moorcroft, Kwon Yon Musick, Philip Marvin Weintraub, Paul Robert Eastwood